Dr. Sarah Premji, Dr. Reshma Mahtani & Dr. Eleftherios Mamounas - Expanding T-DXd Across HER2 + Breast Cancer

Community Health Media · Jun 25, 2026 · 52m

How is trastuzumab deruxtecan (T-DXd) reshaping treatment across early-stage and metastatic HER2-positive breast cancer?

Dr. Sarah Premji, Dr. Reshma Mahtani, and Dr. Eleftherios "Terry" Mamounas discuss the practice-changing implications of DESTINY-Breast11, DESTINY-Breast05, and DESTINY-Breast09, exploring how T-DXd is moving earlier in the treatment paradigm and influencing decision-making from the neoadjuvant setting through first-line metastatic disease.

The conversation examines pathologic complete response (pCR), residual disease management, toxicity monitoring, multidisciplinary care…